- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07903688
Meditation and Yogic Breathing-driven Modulation of Neurofluid Coupling and Brain Clearance (SPANDHA)
This study will examine whether meditation and yogic breathing can alter brain fluid movement and waste clearance in healthy adults. It will also evaluate the GLYMPHOMETER, a new external forehead-worn device designed to objectively measure changes in brain fluid movement and exchange during meditation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The glymphatic system is a brain waste-clearance pathway that facilitates the movement of cerebrospinal fluid (CSF) and interstitial fluid and is thought to play an important role in maintaining brain homeostasis. Emerging evidence suggests that respiration, autonomic activity, and changes in cerebral blood flow may influence CSF dynamics and related neurofluid processes. However, the effects of voluntary breathing practices and meditation on these physiological mechanisms in humans remain incompletely understood.
The SPANDHA study will investigate whether structured yogic breathing (Pranayama; specifically Nadi Shuddhi) and/or meditation (Shoonya meditation) are associated with changes in neurofluid dynamics and related physiological measures. The study will use the GLYMPHOMETER, a forehead-mounted multimodal device designed to measure physiological signals associated with neurofluid coupling during naturalistic meditation and breathing practices. The system incorporates multi-wavelength electroencephalography (EEG) and near-infrared spectroscopy (NIRS) to characterize changes in cerebral electrical activity, cerebral hemodynamics, and neurofluid-related dynamics while participants engage in the interventions.
The study will enroll approximately 100 participants, including 50 novice and 50 experienced practitioners. Using a 2-sequence crossover, participants will complete two study visits involving meditation and yogic breathing conditions. The study will evaluate changes in measures of neurofluid dynamics, cerebral compliance, autonomic regulation including heart-rate variability (HRV), and EEG-derived brain states associated with the interventions. Participants will be stratified by experience level (novice/advance) and randomized within each stratum to one of the two intervention sequences.
A subset of participants will undergo additional validation assessments using phase-contrast magnetic resonance imaging (MRI) and blood-based biomarkers. These assessments will be used to examine the relationship between measurements obtained with the GLYMPHOMETER and established measures of CSF and cerebrovascular physiology.
The primary objective of the study is to characterize the acute physiological effects of meditation and yogic breathing on neurofluid dynamics and related brain and autonomic measures. The findings may provide preliminary evidence regarding the feasibility of using voluntary breathing and meditation practices to modulate physiological processes associated with glymphatic function and may inform future studies of non-pharmacological approaches to brain health.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Balachundhar Subramaniam, MD MPH
- Phone Number: (781) 472-0572
- Email: bsubrama@bidmc.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- BIDMC
-
Contact:
- Deepthi R Johal, PhD
- Phone Number: 8574263244
- Email: drajashe@bidmc.harvard.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adults, 25-60 years old.
- Novice or Advanced as defined above.
- Fluent in English.
- Able to travel to BIDMC site for two days approximately 3-7 days apart.
Exclusion Criteria:
- History of neurological and/or neurodegenerative disorders (e.g., epilepsy, stroke, mild cognitive impairment, dementia)
- History of cardiovascular and respiratory illnesses
- History of major psychiatric disorders (e.g., schizophrenia, bipolar disorder)
- Currently diagnosed mental health issues (e.g., anxiety, depression)
- Current use of psychoactive medications, including medications prescribed for anxiety, depression, or other psychiatric conditions, or current use of stimulants or other medications that may substantially affect central nervous system function or study outcomes.
- Skin ailments, abrasions or contusions, particularly located on the forehead and face
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Novice Meditators
Less than 1 year of consistent meditation practice. |
Nadi Shuddhi is a structured yogic breathing practice involving slow, alternating respiration through the left and right nostrils in a prescribed sequence. Shoonya meditation is a structured contemplative practice characterized by conscious non-doing, in which participants maintain a relaxed, alert state while minimizing deliberate attentional selection, cognitive elaboration, and engagement with internal or external stimuli. |
|
Active Comparator: Advanced Meditators
More than 5 years or a minimum of 2500 hours of consistent meditation practice |
Nadi Shuddhi is a structured yogic breathing practice involving slow, alternating respiration through the left and right nostrils in a prescribed sequence. Shoonya meditation is a structured contemplative practice characterized by conscious non-doing, in which participants maintain a relaxed, alert state while minimizing deliberate attentional selection, cognitive elaboration, and engagement with internal or external stimuli. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acquisition of physiological data using the GLYMPHOMETER during meditation and yogic breathing sessions.
Time Frame: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Participants meeting threshold for analyzable device recordings. |
At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurofluid-related physiological measures during Shoonya meditation and Nadi Shuddhi breathing.
Time Frame: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Changes in GLYMPHOMETER-derived measures of neurofluid coupling, during Shoonya meditation and Nadi Shuddhi breathing. (Measurement device: Glymphometer; Measure: Neurofluid coupling aka Fluid dynamics in brain) |
At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
|
Autonomic regulation during Shoonya meditation and Nadi Shuddhi breathing.
Time Frame: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Changes in heart-rate variability (HRV) during Shoonya meditation and Nadi Shuddhi breathing. |
At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
|
Very-low-frequency physiological signal characteristics
Time Frame: At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Changes in predefined very-low-frequency (0.001-0.1 Hz) signal characteristics derived from GLYMPHOMETER medical™ recordings and their relationship to neurofluid-related measures. |
At each study visit while the meditation is being practiced. Expected acquisition window: 20 minutes; Total number of visits: 2
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in neurophysiological responses according to meditation experience.
Time Frame: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
Comparison of changes in GLYMPHOMETER-derived measures of neurofluid coupling between novice and advanced meditators. |
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
|
Mindful Attention Awareness Scale
Time Frame: Once at Baseline. Estimated acquisition window: 5-8 minutes
|
We assess for change in Mindfulness levels by using a validated scale for this purpose namely, Mindfulness Attention Awareness Scale (MAAS). The scale measures the individuals' ability for receptive awareness and attention to present. This aids in evaluating any change on the individual's awareness levels after the Inner engineering intervention. We compute the MAAS scores for each participant which is a mean score for 15 item questionnaires and compare the pre & post intervention results to look for change. Participants are asked to rate on a scale of 1 (Almost Always) to 6 (Almost Never) to assess the frequency of occurrence of each experience. Mean is then computed using items from each of the 15 questions to create a MAAS score, ranging from 0 to 6. Higher MAAS scores indicate better mindfulness state. |
Once at Baseline. Estimated acquisition window: 5-8 minutes
|
|
Meditation Depth Questionnaires
Time Frame: At each study visit after the meditation practice is completed. Expected acquisition window: 10-15 minutes; Total number of visits: 2
|
This 30-item measure assesses the subjective depth of meditation across progressively deeper experiential states. Items are typically rated on a 5-point Likert scale and are grouped into five empirically derived domains: hindrances, relaxation, personal-self/concentration, essential/transpersonal qualities, and transpersonal-self/non-duality. Together, these domains capture experiences ranging from obstacles and relaxation during meditation to focused concentration, transpersonal qualities, and experiences of diminished self-boundaries or non-dual awareness. |
At each study visit after the meditation practice is completed. Expected acquisition window: 10-15 minutes; Total number of visits: 2
|
|
Correlation between GLYMPHOMETER-derived neurofluid metrics and MRI-based neurofluid dynamics (Validation of Portable Device).
Time Frame: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
This outcome evaluates the concurrent validity of the portable device against the gold standard. The statistical method will be a correlation analysis (Pearson or Spearman, as appropriate based on data distribution).
|
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
|
Correlation between GLYMPHOMETER-derived neurofluid metrics and plasma brain-derived biomarkers.
Time Frame: From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
This outcome evaluates the relationship between neurofluid dynamics and blood-based markers of brain clearance. The statistical method will be a correlation analysis (Pearson or Spearman).
|
From date of enrollment until end of both study visits; assessed up to 4 weeks from enrollment.
|
|
Qualitative assessment of meditation and breathing experiences.
Time Frame: At each study visit after the meditation practice is completed. Expected acquisition window: 30 minutes; Total number of visits: 2
|
Qualitative characterization of participant experiences using one-on-one micro-phenomenological interviews. |
At each study visit after the meditation practice is completed. Expected acquisition window: 30 minutes; Total number of visits: 2
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2026P000655
- GRT69415 (Other Grant/Funding Number: Inner Science Research Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.